IONSIonis Pharmaceuticals Inc
$73.75
$0.545
(0.74%)
Closed $73.28
$0.475
(0.65%)
After Hours
EarningsAug 5
Mkt Cap$12.11B
Vol1.96M
Fundamentals
Mkt Cap
$12.11B
Volume
-
52W High
$86.74
52W Low
$34.78
PE Ratio
-34.86
Avg. Volume
1.67M
EPS (Annual)
-$2.38
Rev/Employee
$673,117.69
Earnings
Aug 05
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.We are pleased to welcome Dr. Hantson to the board, said Joseph Loscalzo, M.D., Ph.D...
Business Wire
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Zacks
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented...
Business Wire
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published...
Business Wire
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Zacks
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimers disease
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an...
Business Wire
Tweedy Browne Co LLC Decreases Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
Tweedy Browne Co LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with...
MarketBeat
Ionis to host 2026 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4...
Business Wire
What is HC Wainwright's Estimate for IONS Q1 Earnings?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ionis Pharmaceuticals in a report released on Thursday, April 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earni...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest IONS News
ViewIonis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Business Wire
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Zacks
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Business Wire
Advertisement|Remove ads.